According to reports in the diabetes news, diabetes drug company AtheroGenics Inc. have claimed that their experimental diabetic drug AGI-1067 has passed main goals in clinical trials . The drug has apparently helped to treat people with type 2 diabetes by reducing blood glucose levels.
The trial, called ANDES, is investigating two different dosages of the drug, 75mg and 150mg. The company will now continue to analyse the trial data, and conduct a further additional trial in line with Food and Drug Administration development plan.
Industry reports indicate that AtheroGenics are in discussion with various potential partners, but the Chief Executive of the company warned that he could not give further details until anything was confirmed.
Diabetes drug trial hits goal
Fri, 01 Aug 2008
Recommended links
Diabetes newsletterDiabetes based financial services
Diabetes forum
Diabetes signs and symptoms
Diabetes trial gives positive feedback
Heart disease may hide diabetes
Groundbreaking Asian diabetes trial
New diabetes drug undergoing trials
New study contradicts trial
New Joslin diabetes trial
Diabetes drug positive phase 2 trial
Largest ever type 2 diabetes trial complete
Diabetes trial gives positive feedback
Diabetes treatment succeeds in Russian trial
Patients in new AtheroGenics trial
Drug company will continue diabetes trial
Eli Lilly initiate joint clinical trial for oral insulin
Diabetes reversed in mice, FDA approves human trial
